Biogen’s controversial Alzheimer’s drug generates $2 million in first few weeks after approval
Aduhelm by BiogenSource: BiogenBiogen's Alzheimer's drug, Adhulem, generated $2 million in revenue in the first few weeks of its approval, the company said…